BACKGROUND: US national guidelines recommend assessing short-acting beta-agonist (SABA) medication use as a marker of asthma severity and control. However, the relationship between recent SABA use and asthma exacerbations is not currently known. OBJECTIVE: To evaluate the proximal relationship between the type and frequency of SABA use and asthma-related outcomes. METHODS: We evaluated SABA use among patients withasthma ages 5 to 56 years who were members of a large health maintenance organization in southeast Michigan. Frequency of use was estimated from pharmacy data assessing the timing and amount of SABA fills. Cox proportional hazards models were used to examine the prospective relationship between average daily SABA use for 3 months and outcomes associated with poor asthma control (ie, oral corticosteroids use, asthma-related emergency department visits, and asthma-related hospitalizations). We separately accounted for SABA metered-dose inhaler (MDI) and SABA nebulizer use. RESULTS: Of the 2,056 patients who met study criteria, 1,569 (76.3%) had used a SABA medication in their baseline year. After adjusting for potential confounders, SABA nebulizer use was associated with asthma-related emergency department visits (adjusted hazard ratio [aHR], 6.32; 95% confidence interval [CI], 2.38 to 16.80) and asthma-related hospitalizations (aHR, 21.62; 95% CI, 3.17 to 147.57). In contrast, frequency of SABA MDI use was not associated with these outcomes. CONCLUSIONS: Frequency of SABA use during a 3-month period was associated with poor asthma outcomes. The relationship with poor asthma outcomes was strongest for SABA nebulizer use, suggesting that the type of SABA used is also of prognostic importance.
RCT Entities:
BACKGROUND: US national guidelines recommend assessing short-acting beta-agonist (SABA) medication use as a marker of asthma severity and control. However, the relationship between recent SABA use and asthma exacerbations is not currently known. OBJECTIVE: To evaluate the proximal relationship between the type and frequency of SABA use and asthma-related outcomes. METHODS: We evaluated SABA use among patients with asthma ages 5 to 56 years who were members of a large health maintenance organization in southeast Michigan. Frequency of use was estimated from pharmacy data assessing the timing and amount of SABA fills. Cox proportional hazards models were used to examine the prospective relationship between average daily SABA use for 3 months and outcomes associated with poor asthma control (ie, oral corticosteroids use, asthma-related emergency department visits, and asthma-related hospitalizations). We separately accounted for SABA metered-dose inhaler (MDI) and SABA nebulizer use. RESULTS: Of the 2,056 patients who met study criteria, 1,569 (76.3%) had used a SABA medication in their baseline year. After adjusting for potential confounders, SABA nebulizer use was associated with asthma-related emergency department visits (adjusted hazard ratio [aHR], 6.32; 95% confidence interval [CI], 2.38 to 16.80) and asthma-related hospitalizations (aHR, 21.62; 95% CI, 3.17 to 147.57). In contrast, frequency of SABA MDI use was not associated with these outcomes. CONCLUSIONS: Frequency of SABA use during a 3-month period was associated with poor asthma outcomes. The relationship with poor asthma outcomes was strongest for SABA nebulizer use, suggesting that the type of SABA used is also of prognostic importance.
Authors: W O Spitzer; S Suissa; P Ernst; R I Horwitz; B Habbick; D Cockcroft; J F Boivin; M McNutt; A S Buist; A S Rebuck Journal: N Engl J Med Date: 1992-02-20 Impact factor: 91.245
Authors: Katrina F Hurley; Joan Sargeant; Jack Duffy; Ingrid Sketris; Doug Sinclair; James Ducharme Journal: Ann Emerg Med Date: 2007-06-07 Impact factor: 5.721
Authors: Adam J Spanier; Robert S Kahn; Richard Hornung; Michelle Lierl; Bruce P Lanphear Journal: Pediatr Allergy Immunol Pulmonol Date: 2011-03 Impact factor: 1.349
Authors: Karen E Wells; Edward L Peterson; Brian K Ahmedani; Richard K Severson; Julie Gleason-Comstock; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-01-26 Impact factor: 10.793
Authors: L Keoki Williams; Edward L Peterson; Karen Wells; Brian K Ahmedani; Rajesh Kumar; Esteban G Burchard; Vimal K Chowdhry; David Favro; David E Lanfear; Manel Pladevall Journal: J Allergy Clin Immunol Date: 2011-10-21 Impact factor: 10.793
Authors: Arlene M Butz; Jean Ogborn; Shawna Mudd; Jeromie Ballreich; Mona Tsoukleris; Joan Kub; Melissa Bellin; Mary Elizabeth Bollinger Journal: Ann Allergy Asthma Immunol Date: 2015-03-31 Impact factor: 6.347
Authors: L Keoki Williams; Edward L Peterson; Karen Wells; Janis Campbell; Mingqun Wang; Vimal K Chowdhry; Matthew Walsh; Robert Enberg; David E Lanfear; Manel Pladevall Journal: J Allergy Clin Immunol Date: 2010-05-31 Impact factor: 10.793
Authors: Sonia Cajigal; Karen E Wells; Edward L Peterson; Brian K Ahmedani; James J Yang; Rajesh Kumar; Esteban G Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Pract Date: 2016-08-17
Authors: Anna Jetske Baron; Bertine M J Flokstra-de Blok; Huib A M Kerstjens; Gineke Koopmans-Klein; David B Price; Andrea A Sellink; Ioanna Tsiligianni; Janwillem W H Kocks Journal: J Asthma Allergy Date: 2021-07-12